Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for MindMaze Therapeutics Holding's EV-to-FCF or its related term are showing as below:
XSWX:MMTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.5 Med: 0 Max: 0
Current: -3.5
XSWX:MMTX's EV-to-FCF is ranked worse than 100% of 315
companies
in the Biotechnology industry
Industry Median: 15.06
vs XSWX:MMTX: -3.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MindMaze Therapeutics Holding's PE Ratio (TTM) for today is calculated as:
MindMaze Therapeutics Holding's share price for today is CHF0.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MindMaze Therapeutics Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MindMaze Therapeutics Holding EV-to-FCF Related Terms
MindMaze Therapeutics Holding EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding EV-to-FCF Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
EV-to-FCF
0.00
-39.04
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Jun25
Dec25
Jun26
EV-to-FCF
0.00
0.00
0.00
0.00
XSWX:MMTX vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's EV-to-FCF falls into.
MindMaze Therapeutics Holding's current Enterprise Value is CHF25.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MindMaze Therapeutics Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-13.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding (XSWX:MMTX) has a EV-to-FCF of -1.87 as of Sep. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 315 companies in the Biotechnology industry.
Is MindMaze Therapeutics Holding's EV-to-FCF too high?
MindMaze Therapeutics Holding's current EV-to-FCF is -1.87. Based on the distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 315 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 315 companies for EV-to-FCF. This places MindMaze Therapeutics Holding in the lower half of its industry. The industry median EV-to-FCF is 15.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.06, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current EV-to-FCF is -1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current EV-to-FCF of -1.87. The current EV-to-FCF is -1.87. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current EV-to-FCF is -1.87 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
